{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T12:46:12Z","timestamp":1777898772066,"version":"3.51.4"},"reference-count":40,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Public Health Rep"],"abstract":"<jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>Although the existing literature highlights the success of pharmacist-led hepatitis C virus (HCV) treatment, the impact of these models on time to treatment initiation has not been studied. This study compared outcomes for HCV treatment using direct-acting antivirals (DAAs) in 2 groups: pharmacist-led programs in 5 federally qualified health centers in Ohio and an external cohort from an out-of-state academic medical center. We assessed the time to HCV treatment initiation, rates of DAA initiation, and sustained virologic response (SVR) rates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort analysis using electronic health records and pharmacy claims for patients with HCV referred to pharmacists from November 2021 through December 2023. We collected data on demographic characteristics, pre-entry characteristics, treatment initiation rates, time to initiation, and cure rates. The treatment initiation rate included all patients referred to a pharmacy. We defined time to initiation as the period from pharmacy referral to the date of medication pickup. We defined cure as achieving SVR 12 weeks posttreatment (SVR12) and analyzed SVR12 rates in an intent-to-treat and per-protocol manner. We compared time to initiation with an external cohort median of 300 days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Of 477 referred patients, 317 (66.5%) initiated DAAs. The mean (SD) time to treatment initiation was 63.7 (74.2) days, with a median of 37 days. Among the 212 patients completing SVR12 laboratory tests, 194 achieved cure, yielding a per-protocol SVR12 of 91.5% and an intent-to-treat SVR12 of 61.2%. Patients without (vs with) health insurance and with (vs without) a history of substance abuse had longer treatment delays.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>This study demonstrates the value of integrating pharmacists into HCV treatment teams to meet public health needs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/00333549251372037","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:11:38Z","timestamp":1761808298000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacist Involvement in Hepatitis C Management and Time to Treatment Initiation in Medically Underserved Primary Care Settings"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-0306-9804","authenticated-orcid":false,"given":"Kenneth","family":"Furdich","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, Northeast Ohio Medical University, Rootstown, OH, USA"},{"name":"AxessPointe Community Health Centers, Akron, OH, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdi","family":"Awad","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Northeast Ohio Medical University, Rootstown, OH, USA"},{"name":"AxessPointe Community Health Centers, Akron, OH, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Maguire","sequence":"additional","affiliation":[{"name":"PrimaryOne Health, Columbus, OH, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9107-9724","authenticated-orcid":false,"given":"Alexa S.","family":"Valentino","sequence":"additional","affiliation":[{"name":"PrimaryOne Health, Columbus, OH, USA"},{"name":"College of Pharmacy, The Ohio State University, Columbus, OH, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Staudt","sequence":"additional","affiliation":[{"name":"Heart of Ohio Family Health, Columbus, OH, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas G.","family":"Nelson","sequence":"additional","affiliation":[{"name":"Southeast Healthcare, St. Clairsville, OH, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy","family":"Church","sequence":"additional","affiliation":[{"name":"Southeast Healthcare, St. Clairsville, OH, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barlow","family":"Wagner","sequence":"additional","affiliation":[{"name":"Southeast Healthcare, St. Clairsville, OH, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priscilla","family":"Tutu","sequence":"additional","affiliation":[{"name":"Heart of Ohio Family Health, Columbus, OH, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janessa","family":"Cohrs","sequence":"additional","affiliation":[{"name":"Heart of Ohio Family Health, Columbus, OH, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Paul","sequence":"additional","affiliation":[{"name":"NeighborHub Health, Cincinnati, OH, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"key":"e_1_3_2_2_2","volume-title":"Global Hepatitis Report 2024: Action for Access in Low- and Middle-Income Countries","author":"World Health Organization","year":"2024","unstructured":"World Health Organization. Global Hepatitis Report 2024: Action for Access in Low- and Middle-Income Countries. World Health Organization; 2024."},{"key":"e_1_3_2_3_2","unstructured":"Centers for Disease Control and Prevention. Universal hepatitis C screening among adults and treatment for hepatitis C virus infection. 2024. Accessed July 21 2025. https:\/\/www.cdc.gov\/high-impact-prevention\/php\/case-studies\/hepatitis-c-screening-treatment.html"},{"key":"e_1_3_2_4_2","unstructured":"Congressional Budget Office. Budgetary effects of policies that would increase hepatitis C treatment. 2024. Accessed July 9 2025. https:\/\/www.cbo.gov\/publication\/60407"},{"key":"e_1_3_2_5_2","unstructured":"World Health Organization. Global Health Sector Strategies on Respectively HIV Viral Hepatitis and Sexually Transmitted Infections for the Period 2022-2030. World Health Organization; 2022. Accessed February 1 2024. https:\/\/iris.who.int\/handle\/10665\/360348"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1049"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1177\/08971900231165172"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1177\/00333549211015664"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31060"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12875-024-02507-0"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz316"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxz034"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2019.01.018"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadr.2023.100213"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(20)30120-5"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2022.04.014"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2022.09.006"},{"key":"e_1_3_2_18_2","volume-title":"A National Strategy for the Elimination of Hepatitis B and C: Phase Two Report","author":"National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Population Health and Public Health Practice; Committee on a National Strategy for the Elimination of Hepatitis B and C","year":"2017","unstructured":"National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Population Health and Public Health Practice; Committee on a National Strategy for the Elimination of Hepatitis B and C; Strom BL, Buckley GJ, eds. A National Strategy for the Elimination of Hepatitis B and C: Phase Two Report. National Academies Press; 2017."},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(17)30375-3"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1002876"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-021-06761-1"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.2147\/JMDH.S284885"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0218759"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.11.008"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7132e1"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2021.05.017"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.27326"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(22)00346-6"},{"issue":"11","key":"e_1_3_2_29_2","first-page":"616","article-title":"Update on the treatment of hepatitis C virus infection in patients with cirrhosis","volume":"15","author":"Pockros PJ.","year":"2019","unstructured":"Pockros PJ. Update on the treatment of hepatitis C virus infection in patients with cirrhosis. Gastroenterol Hepatol (N Y). 2019;15(11):616-618.","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13399"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/add.14217"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit296"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1702417"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(18)30341-8"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy220"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(17)30404-1"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-023-00823-z"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.09.018"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2015.31"},{"key":"e_1_3_2_40_2","unstructured":"National Viral Hepatitis Roundtable. United States national hepatitis C elimination initiative. 2025. Accessed July 14 2024. https:\/\/www.globalhep.org\/advocacy\/united-states-national-hepatitis-c-elimination-initiative"},{"key":"e_1_3_2_41_2","unstructured":"National Viral Hepatitis Roundtable Center for Health Law and Policy Innovation of Harvard Law School. Hepatitis C: state of Medicaid access. August 2023 Snapshot Update. August 2023. Accessed January 18 2025. https:\/\/stateofhepc.org\/wp-content\/uploads\/2024\/02\/August-2023-SOHC-Update.pdf"}],"container-title":["Public Health Reports\u00ae"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00333549251372037","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/00333549251372037","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00333549251372037","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T09:40:34Z","timestamp":1777628434000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/00333549251372037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":40,"alternative-id":["10.1177\/00333549251372037"],"URL":"https:\/\/doi.org\/10.1177\/00333549251372037","relation":{},"ISSN":["0033-3549","1468-2877"],"issn-type":[{"value":"0033-3549","type":"print"},{"value":"1468-2877","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,30]]},"article-number":"00333549251372037"}}